JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1677/joe.0.1620111

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phillips, D.
Right arrow Articles by Hedger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phillips, D.
Right arrow Articles by Hedger, M.
Journal of Endocrinology, Vol 162, Issue 1, 111-116
Copyright © 1999 by Society for Endocrinology


Articles

A sensitive and specific in vitro bioassay for activin using a mouse plasmacytoma cell line, MPC-11

DJ Phillips, JN Brauman, AJ Mason, DM de Kretser, and MP Hedger


A new in vitro bioassay for activin was developed using the mouse plasmacytoma cell line, MPC-11. Human recombinant (hr) activin A dose-dependently inhibited the proliferation of these cells, whereas a range of other factors, including inhibin, follistatin and transforming growth factor-beta1, -beta2 and -beta3 had no effect. Conditioned medium containing activin B induced an inhibition similar to hr-activin A. The inhibitory influence of activin A could be blocked by follistatin, but not by hr-inhibin A. This bioassay had a sensitivity for activin A of around 0.4 ng/ml, an ED50 response of 3.5 ng/ml, and an intra-assay coefficient of variation of <11%. It offers substantial advantages over existing in vitro activin bioassays in terms of ease of use, specificity and throughput. The utility of the MPC-11 bioassay was demonstrated in the purification of activin from amniotic fluid, where an almost identical profile of bioactive activin A was detected compared with the pituitary cell bioassay of activin. Bioactive activin could also be detected in unpurified ovine allantoic and amniotic fluids and bovine follicular fluid. Measuring activin in untreated and heat-treated human sera or seminal plasma was hampered by a non-specific inhibitory effect, so that several serum samples did not run parallel with the hr-activin A standard. This inhibitory effect by serum could not be overcome by addition of follistatin, suggesting it is not activin-like bioactivity. This new bioassay for activin demonstrates widespread applicability for monitoring of purified or partially purified samples during purification procedures, bioactivity measurements, receptor-binding studies and assays of cell culture medium.


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. Kotzsch, J. Nickel, A. Seher, K. Heinecke, L. van Geersdaele, T. Herrmann, W. Sebald, and T. D. Mueller
Structure Analysis of Bone Morphogenetic Protein-2 Type I Receptor Complexes Reveals a Mechanism of Receptor Inactivation in Juvenile Polyposis Syndrome
J. Biol. Chem., February 29, 2008; 283(9): 5876 - 5887.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
Y. Shav-Tal and D. Zipori
The Role of Activin A in Regulation of Hemopoiesis
Stem Cells, November 1, 2002; 20(6): 493 - 500.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. R. McFarlane, L. M. Foulds, A. E. O’Connor, D. J. Phillips, G. Jenkin, M. T. W. Hearn, and D. M. de Kretser
Uterine Milk Protein, a Novel Activin-Binding Protein, Is Present in Ovine Allantoic Fluid
Endocrinology, October 1, 1999; 140(10): 4745 - 4752.
[Abstract] [Full Text]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society for Endocrinology.